{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:39:15Z","timestamp":1791362355234,"version":"4.3.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["2022-GRIN-34354"],"award-info":[{"award-number":["2022-GRIN-34354"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011698","name":"Junta de Comunidades de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.arr.2023.102012","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T12:19:18Z","timestamp":1688732358000},"page":"102012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Danko","family":"Jeremic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Navarro-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Jim\u00e9nez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.102012_bib1","unstructured":"Alzforum, 2023a. Aduhelm, https:\/\/www.alzforum.org\/therapeutics\/aduhelm."},{"key":"10.1016\/j.arr.2023.102012_bib2","unstructured":"Alzforum, 2023b. Leqembi, https:\/\/www.alzforum.org\/therapeutics\/leqembi."},{"key":"10.1016\/j.arr.2023.102012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2023.102012_bib4","doi-asserted-by":"crossref","unstructured":"Borenstein, M., Hedges, L.V., Higgins, J.P., Rothstein, H.R., 2021. Introduction to meta-analysis, 2nd ed. John Wiley & Sons.","DOI":"10.1002\/9781119558378"},{"key":"10.1016\/j.arr.2023.102012_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102012_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102012_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.arr.2023.102012_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fneur.2015.00207","article-title":"Anti-A\u03b2 autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy","volume":"6","author":"DiFrancesco","year":"2015","journal-title":"Front Neurol."},{"key":"10.1016\/j.arr.2023.102012_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102012_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel\u2010plot\u2013based method of testing and adjusting for publication bias in meta\u2010analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.arr.2023.102012_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1198\/016214502760047131","article-title":"Model-based clustering, discriminant analysis, and density estimation","volume":"97","author":"Fraley","year":"2002","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.arr.2023.102012_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0091270007304776","article-title":"Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems","volume":"47","author":"Glasser","year":"2007","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.arr.2023.102012_bib13","doi-asserted-by":"crossref","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T.A., Ebert, D.D., 2021. Doing meta-analysis with R: A hands-on guide. Chapman and Hall\/CRC.","DOI":"10.1201\/9781003107347"},{"key":"10.1016\/j.arr.2023.102012_bib14","first-page":"100","article-title":"Algorithm AS 136: a k-means clustering algorithm","volume":"28","author":"Hartigan","year":"1979","journal-title":"J. R. Stat. Soc. Ser. C. (Appl. Stat. )"},{"key":"10.1016\/j.arr.2023.102012_bib15","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.arr.2023.102012_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102012_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106631","article-title":"Role of monomeric amyloid-\u03b2 in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies","volume":"187","author":"Imbimbo","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.arr.2023.102012_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.arr.2023.102012_bib19","article-title":"Alzheimer's disease: have we opened the golden gate to disease-modifying therapy?","author":"Isaacs","year":"2022","journal-title":"Cereb. Circ. -Cogn. Behav."},{"key":"10.1016\/j.arr.2023.102012_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.arr.2023.102012_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review","volume":"72","author":"Jeremic","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2023.102012_bib22","first-page":"29","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","author":"J\u00f6nsson","year":"2023","journal-title":"Lancet Reg. Health"},{"key":"10.1016\/j.arr.2023.102012_bib23","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2023.102012_bib24","article-title":"Regulatory decisions diverge over aducanumab for Alzheimer\u2019s disease","volume":"376","author":"Lythgoe","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2023.102012_bib25","doi-asserted-by":"crossref","first-page":"n3127","DOI":"10.1136\/bmj.n3127","article-title":"Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2023.102012_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.p73","article-title":"Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2023.102012_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth. Methods"},{"key":"10.1016\/j.arr.2023.102012_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/alz.069405","article-title":"Lifetime clinical benefits of lecanemab in early Alzheimer\u2019s disease using simulation modeling","volume":"18","author":"Monfared","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2023.102012_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/alz.069428","article-title":"ENVISION: a phase 3b\/4 randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab in participants with early Alzheimer\u2019s disease","volume":"18","author":"Murphy","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2023.102012_bib30","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer's disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.102012_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH - a graphical display of study heterogeneity","volume":"3","author":"Olkin","year":"2012","journal-title":"Res Synth. Methods"},{"key":"10.1016\/j.arr.2023.102012_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2023.102012_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer's disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2023.102012_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of Alzheimer's disease: a systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.arr.2023.102012_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2023.102012_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.102012_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102012_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1145\/3068335","article-title":"DBSCAN revisited, revisited: why and how you should (still) use DBSCAN","volume":"42","author":"Schubert","year":"2017","journal-title":"ACM Trans. Database Syst. (TODS)"},{"key":"10.1016\/j.arr.2023.102012_bib39","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2023.102012_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of Anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2023.102012_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2023.102012_bib42","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1007\/s12035-015-9390-0","article-title":"Dissecting complex and multifactorial nature of alzheimer's disease pathogenesis: a clinical, genomic, and systems biology perspective","volume":"53","author":"Talwar","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2023.102012_bib43","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/brain\/awaa325","article-title":"Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics","volume":"143","author":"Tijms","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.arr.2023.102012_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102012_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.102012_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth. Methods"},{"key":"10.1016\/j.arr.2023.102012_bib47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects","volume":"178","author":"Villain","year":"2022","journal-title":"Rev. Neurol. (Paris)"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372300171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372300171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:22:35Z","timestamp":1761592955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156816372300171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"alternative-id":["S156816372300171X"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.102012","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.102012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102012"}}